Managed Care Meeting Will Focus on Diabetes Patient Outcomes

  • Mar 2019

On Thursday April 4, The American Journal of Managed Care will host a regional Institute for Value-Based Medicine® meeting on the advances in treatment and management to reduce cost and improve outcomes of patients with diabetes  from 5:30-9:00 p.m. at The Statler Dallas in Texas.

This meeting will feature four presenters: Endocrine Society member Jaime Davidson, MD, FACP, MACE, clinical professor of medicine at Touchstone Diabetes Center in the division of endocrinology, diabetes, and metabolism at the University of Texas (UT) Southwestern Medical Center, will be the chairman and moderator;Ian Neeland, MD, assistant professor in the department of internal medicine at UT Southwestern Medical Center; Jennifer Reed, LCSW, vice president of comprehensive care management at Baylor Scott & White Health; and Kellie Rodriguez, RN, MSN, MBA, CDE, director of the global diabetes program at Parkland Health & Hospital System.

The Institute for Value-Based Medicine® is an informative regional series that focuses on multi-stakeholder perspectives from physicians, payers and practice executives. With a goal to discuss pressing topics, such as the implications of value-based medicine on clinical practice, best practices in team-based diabetes care from leading health systems, and innovative models for population health management, the program features leading clinicians and managed care experts.

Click here for more information.

You may also like

  • Circulating microRNAs Likely as Effective as A1C for Predicting Type 2 Diabetes in Youth

    Measuring the circulating abundance of microRNAs is likely as effective as measuring the level of sugar in the blood for determining how a young person with the condition will fare, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Jeanie Tryggestad, MD, an associate professor of pediatrics…

  • Two Medication Classes Reduced Cardiovascular and Liver Events in People with Type 2 Diabetes

    GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed…

Find more in